Adaptive Biotechnologies supplies the Royal Marsden's clonoSEQ MRD assay
- The Royal Marsden NHS Foundation Trust
- London
- Direct
- 20 January 2026 to 19 January 2031
The Royal Marsden NHS Foundation Trust buys the clonoSEQ assay from Adaptive Biotechnologies Corporation to track minimal residual disease (MRD) in blood cancer patients. The next-generation sequencing test covers conditions such as chronic lymphocytic leukaemia, acute lymphoblastic leukaemia and multiple myeloma.
The trust required a test that works on DNA, reaches an MRD sensitivity of 10⁻⁵ or lower and can track clonal evolution. Alongside the kits and reagents, Adaptive provides training and support for laboratory and clinical staff, plus a software platform to analyse and report results.
The trust awarded the £1,158,208 contract directly. It runs for five years, from January 2026 to January 2031.
Contract ends January 2031
- What
- Genomic sequencing platforms and consumables
- Value
- £1.16m
- How it was bought
- Direct
- Dates and next
- Jan 2026 to Jan 2031